Home-based Circuit Training for People With Intermittent Claudication (WALKSTRONG)
Primary Purpose
Peripheral Artery Disease, Intermittent Claudication
Status
Completed
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Exercise group
Sponsored by
About this trial
This is an interventional treatment trial for Peripheral Artery Disease focused on measuring home-based exercise, circuit training, walking
Eligibility Criteria
Inclusion Criteria:
- Ankle/brachial index (ABPI) < 0.9 at rest or a drop of 20mmHg after exercise testing
- Ability to walk independently
- English speaking
- Able to follow instructions
- ≥ 18 years of age
Exclusion Criteria:
- Unable to provide informed consent
- Walking impairment for a reason that is not PAD
- Critical limb ischaemia
- Asymptomatic PAD
- Active cancer treatment
- Severe mental or physical limitations precluding participation safely in the home environment
Sites / Locations
- Coventry University
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
Exercise group
Usual care
Arm Description
Home-based circuit and community walking exercise
Usual activity/healthcare
Outcomes
Primary Outcome Measures
Intervention feasibility assessed via recruitment rate
The investigators will record the number of eligible participants, as well as the number who enroll onto the study.
Intervention feasibility assessed via attrition rate
The investigators will record the number of protocol discontinuations and losses to follow-up.
Intervention feasibility assessed via protocol adherence
The investigators will examine discrepancies between intervention prescription and what is completed.
Intervention acceptability via participant interviews
One-to-one interviews will be held between an investigator and participant who has either completed the intervention, withdrawn or declined participation, to ask questions regarding the intervention protocol.
Secondary Outcome Measures
12 and 24 week change in six-minute walk distance and pain-free walk distance
Change in six-minute and pain-free walk distance after 12 and 24 weeks will be compared to participants randomised to the exercise group vs the usual care group.
12 and 24 week change in pain-free and maximal treadmill walk distance
Change in pain-free and maximal treadmill walk distance after 12 and 24 weeks will be compared to participants randomised to the exercise group vs the usual care group.
12 and 24 weeks change in left and right hand grip strength (via hand held dynamometer)
Change in left and right hand grip strength after 12 and 24 weeks will be compared to participants randomised to the exercise group vs the usual care group.
12 and 24 week change in physical activity measured by accelerometer data
Change in physical activity behaviour at 12 and 24 weeks will be compared to participants randomised to the exercise group vs the usual care group, using accelerometer data.
12 and 24 week change in SF-36 score
Change in 36 Item Short Form survey scores at 12 and 24 weeks will be compared to participants randomised to the exercise group vs the usual care group. (Score ranges from 0-100, with higher scores associated with a better outcome).
12 and 24 week change in VascuQol questionnaire score
Change in Vascular Quality of Life questionnaire scores at 12 and 24 weeks will be compared to participants randomised to the exercise group vs the usual care group. (Score ranges from 1-7, with higher scores associated with a better outcome).
12 and 24 week change in EQ-5D-5L questionnaire score
Change in European Quality of Life Five Dimension questionnaire scores at 12 and 24 weeks will be compared to participants randomised to the exercise group vs the usual care group. (Scores range from 1-5, with lower scores associated with a better outcome).
12 and 24 week change in circulating markers of inflammation
Investigators will compare blood sample measures of IL-6, TNF-α, CRP between participants randomised to the exercise group vs the usual care group at 12 and 24 weeks.
12 and 24 week change in circulating markers of vascular remodelling
Investigators will compare blood sample measures of VEGF between participants randomised to the exercise group vs the usual care group at 12 and 24 weeks.
Full Information
NCT ID
NCT05059899
First Posted
September 17, 2021
Last Updated
August 21, 2023
Sponsor
Coventry University
Collaborators
University Hospitals Coventry and Warwickshire NHS Trust
1. Study Identification
Unique Protocol Identification Number
NCT05059899
Brief Title
Home-based Circuit Training for People With Intermittent Claudication
Acronym
WALKSTRONG
Official Title
Community WALKing and Home-baSed circuiT tRaining in peOple liviNG With Intermittent Claudication (WALK-STRONG): a Randomised Controlled Feasibility Trial
Study Type
Interventional
2. Study Status
Record Verification Date
August 2023
Overall Recruitment Status
Completed
Study Start Date
May 9, 2022 (Actual)
Primary Completion Date
June 26, 2023 (Actual)
Study Completion Date
June 26, 2023 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Coventry University
Collaborators
University Hospitals Coventry and Warwickshire NHS Trust
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of the study is to assess the feasibility of undertaking a randomised controlled trial investigating the effectiveness of a 12-week home-based exercise programme for people with intermittent claudication.
Detailed Description
30 participants with PAD will be randomised to one of two groups: either exercise or usual care. The 12 week exercise intervention will consist of a home-based circuit programme, including both resistance exercises and walking. This will be combined with promoting free-living walking throughout the rest of the week. Exercise will be regulated via the use of a wearable activity monitor. Biweekly phone calls will address compliance with the intervention. The primary outcomes are feasibility and acceptability, which will be determined after 12 weeks via recruitment and attrition rates, protocol adherence and with participant interviews. Secondary outcomes include changes in pain-free and maximal walking distances with both a graded treadmill test and six-minute walk test, hand grip strength, physical activity behaviour (measured with an accelerometer), quality of life (measured with the SF-36, VascuQol and E5-5D-5L questionnaires) after 12 and 24 weeks. Investigators will also assess changes in markers of inflammation, vascular remodeling, mitochondrial biogenesis and oxidative stress at 12 and 24 weeks. Other outcomes include changes in time spent resting during a six-minute walk test and time to pain cessation following a graded treadmill test at 12 and 24 weeks.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Peripheral Artery Disease, Intermittent Claudication
Keywords
home-based exercise, circuit training, walking
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
30 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Exercise group
Arm Type
Experimental
Arm Description
Home-based circuit and community walking exercise
Arm Title
Usual care
Arm Type
No Intervention
Arm Description
Usual activity/healthcare
Intervention Type
Behavioral
Intervention Name(s)
Exercise group
Intervention Description
The exercise group will receive a 12-week home-based exercise programme, with a wearable activity watch to regulate physical activity behaviour. This group will also receive biweekly telephone calls from the investigator.
Primary Outcome Measure Information:
Title
Intervention feasibility assessed via recruitment rate
Description
The investigators will record the number of eligible participants, as well as the number who enroll onto the study.
Time Frame
Will be evaluated after the intervention period (i.e.. 24 weeks after inclusion)
Title
Intervention feasibility assessed via attrition rate
Description
The investigators will record the number of protocol discontinuations and losses to follow-up.
Time Frame
Will be evaluated after the intervention period (i.e.. 24 weeks after inclusion)
Title
Intervention feasibility assessed via protocol adherence
Description
The investigators will examine discrepancies between intervention prescription and what is completed.
Time Frame
Will be evaluated after the intervention period (i.e.. 24 weeks after inclusion)
Title
Intervention acceptability via participant interviews
Description
One-to-one interviews will be held between an investigator and participant who has either completed the intervention, withdrawn or declined participation, to ask questions regarding the intervention protocol.
Time Frame
Will be evaluated after the intervention period (either at 12 week or 24 week follow up)
Secondary Outcome Measure Information:
Title
12 and 24 week change in six-minute walk distance and pain-free walk distance
Description
Change in six-minute and pain-free walk distance after 12 and 24 weeks will be compared to participants randomised to the exercise group vs the usual care group.
Time Frame
Baseline to 12 weeks and 24 weeks
Title
12 and 24 week change in pain-free and maximal treadmill walk distance
Description
Change in pain-free and maximal treadmill walk distance after 12 and 24 weeks will be compared to participants randomised to the exercise group vs the usual care group.
Time Frame
Baseline to 12 weeks and 24 weeks
Title
12 and 24 weeks change in left and right hand grip strength (via hand held dynamometer)
Description
Change in left and right hand grip strength after 12 and 24 weeks will be compared to participants randomised to the exercise group vs the usual care group.
Time Frame
Baseline to 12 weeks and 24 weeks
Title
12 and 24 week change in physical activity measured by accelerometer data
Description
Change in physical activity behaviour at 12 and 24 weeks will be compared to participants randomised to the exercise group vs the usual care group, using accelerometer data.
Time Frame
Baseline to 12 weeks and 24 weeks
Title
12 and 24 week change in SF-36 score
Description
Change in 36 Item Short Form survey scores at 12 and 24 weeks will be compared to participants randomised to the exercise group vs the usual care group. (Score ranges from 0-100, with higher scores associated with a better outcome).
Time Frame
Baseline to 12 weeks and 24 weeks
Title
12 and 24 week change in VascuQol questionnaire score
Description
Change in Vascular Quality of Life questionnaire scores at 12 and 24 weeks will be compared to participants randomised to the exercise group vs the usual care group. (Score ranges from 1-7, with higher scores associated with a better outcome).
Time Frame
Baseline to 12 weeks and 24 weeks
Title
12 and 24 week change in EQ-5D-5L questionnaire score
Description
Change in European Quality of Life Five Dimension questionnaire scores at 12 and 24 weeks will be compared to participants randomised to the exercise group vs the usual care group. (Scores range from 1-5, with lower scores associated with a better outcome).
Time Frame
Baseline to 12 weeks and 24 weeks
Title
12 and 24 week change in circulating markers of inflammation
Description
Investigators will compare blood sample measures of IL-6, TNF-α, CRP between participants randomised to the exercise group vs the usual care group at 12 and 24 weeks.
Time Frame
Baseline to 12 weeks and 24 weeks
Title
12 and 24 week change in circulating markers of vascular remodelling
Description
Investigators will compare blood sample measures of VEGF between participants randomised to the exercise group vs the usual care group at 12 and 24 weeks.
Time Frame
Baseline to 12 weeks and 24 weeks
Other Pre-specified Outcome Measures:
Title
12 and 24 week change in rest times during a six-minute walk test
Description
Change in time spent resting during a six-minute walk test after 12 and 24 weeks will be compared to participants randomised to the exercise group vs the usual care group.
Time Frame
Baseline to 12 weeks and 24 weeks
Title
12 and 24 week change in pain cessation following a treadmill test
Description
Change in time to pain cessation following a treadmill test after 12 and 24 weeks will be compared to participants randomised to the exercise group vs the usual care group.
Time Frame
Baseline to 12 weeks and 24 weeks
Title
12 and 24 week changes in walking speed during a six-minute walk test
Description
Change in walking speed during a six-minute walk test after 12 and 24 weeks will be compared to participants randomised to the exercise group vs the usual care group.
Time Frame
Baseline to 12 weeks and 24 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Ankle/brachial index (ABPI) < 0.9 at rest or a drop of 20mmHg after exercise testing
Ability to walk independently
English speaking
Able to follow instructions
≥ 18 years of age
Exclusion Criteria:
Unable to provide informed consent
Walking impairment for a reason that is not PAD
Critical limb ischaemia
Asymptomatic PAD
Active cancer treatment
Severe mental or physical limitations precluding participation safely in the home environment
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Alexander Waddell, MSc
Organizational Affiliation
Coventry University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Coventry University
City
Coventry
State/Province
West Midlands
ZIP/Postal Code
CV1 2DS
Country
United Kingdom
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Home-based Circuit Training for People With Intermittent Claudication
We'll reach out to this number within 24 hrs